We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Daiichi Sankyo conducted a preclinical study with Puma Biotechnology and the Memorial Sloan Kettering Cancer Center to evaluate combination therapy with HER2 mutation / HER2-positive solid tumor therapy.